| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5223510 | SANOFI AVENTIS US | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
Jul, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8318800 | SANOFI AVENTIS US | Solid pharmaceutical compositions containing benzofuran derivatives |
Jun, 2018
(5 years ago) | |
| US7323493 | SANOFI AVENTIS US | Solid pharmaceutical composition containing benzofuran derivatives |
Jun, 2018
(5 years ago) | |
| US9107900 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
Apr, 2029
(4 years from now) | |
| US8410167 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Apr, 2029
(4 years from now) | |
| US8602215 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Jun, 2031
(7 years from now) | |
Multaq is owned by Sanofi Aventis Us.
Multaq contains Dronedarone Hydrochloride.
Multaq has a total of 6 drug patents out of which 3 drug patents have expired.
Expired drug patents of Multaq are:
- US8318800
- US7323493
- US5223510
Multaq was authorised for market use on 01 July, 2009.
Multaq is available in tablet;oral dosage forms.
Multaq can be used as management of risk of dronedarone/beta-blocker interaction in patients in sinus rhythm with a history of paroxysmal or persistent af, treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals, reduction of the risk of cardiovascular hospitalization, reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals.
Drug patent challenges can be filed against Multaq from 01 July, 2013.
The generics of Multaq are possible to be released after 30 June, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2014 |
Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient
NCE-1 date: 01 July, 2013
Market Authorisation Date: 01 July, 2009
Treatment: Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning a...
Dosage: TABLET;ORAL
MULTAQ family patents
